Should You Buy Alnylam Pharmaceuticals Before Feb. 12?

Core Insights - Alnylam Pharmaceuticals is expected to report its Q4 2025 results around February 12, 2026, with investors anticipating a positive catalyst for the stock [1] - Wall Street forecasts total Q4 revenue of $1.16 billion and adjusted earnings per share of $1.50 for Alnylam [2] - The company is likely to report significant growth in Amvuttra sales, which increased by 162% year over year in Q3 2025, primarily driven by its use in transthyretin cardiac amyloidosis (ATTR-CM) [2] Financial Performance - Alnylam's full-year 2025 guidance projects combined sales of Amvuttra and Onpattro at $2.5 billion at the midpoint, with expected growth in Q4 primarily from Amvuttra due to declining sales of Onpattro [3] - The contribution of international markets to Amvuttra sales in Q4 is expected to be modest, with stronger growth anticipated in Germany and Japan in 2026 [4] Operational Updates - As Amvuttra sales increase, the company may experience a decline in gross margin due to rising royalty rates paid to partners [5] - Alnylam is expected to provide updates on its pipeline, including the initiation of a Phase 3 study for nucresiran targeting hereditary ATTR with polyneuropathy and a Phase 2 trial for mivelsiran in Alzheimer's disease [6] Investment Outlook - Alnylam is viewed as a strong long-term investment opportunity, with Amvuttra showing robust momentum and a promising pipeline featuring several late-stage candidates [7]